



09/19/00

09-20-00  
PATENT APPLICATION TRANSMITTAL LETTER

Box/SEC

A

Our Docket No. E1047/20044

To The Commissioner For Patents:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 CFR 1.53 is the patent application of:

Glen H. Erikson and Jasmine I. Daksis

entitled:

QUADRUPLEX DNA AND DUPLEX PROBE SYSTEMS

## Enclosed are:

- ☒ 36 pages of written description, claims and abstract.
- ☒ 5 sheets of drawings.
- ☒ an assignment of the invention to Ingeneus Corporation
- ☒ recordation sheet for assignment
- ☒ executed declaration of the inventor(s) and power of attorney.
- ☐ certified copy of a \_\_\_\_\_ application.
- ☒ verified statement to establish small entity status under 37 CFR 1.9(f) and 1.27(b) - Independent Inventor.
- ☒ verified statement to establish small entity status under 37 CFR 1.9(f) and 1.27(c) - Small Business Concern.
- ☐ information disclosure statement.
- ☐ preliminary amendment.
- ☒ other: Sequence Listing (Paper and CRF)

## CLAIMS AS FILED

	Number Filed	Number Extra	Rate	Fee
BASIC FEE			\$690	\$690
TOTAL CLAIMS	52 - 20 =	32	x 18	\$576
INDEPENDENT CLAIMS	2 - 3 =	0	x 78	\$0
MULTIPLE DEPENDENT CLAIM PRESENT			\$	\$0


Number Extra Must Be Zero or Larger

TOTAL \$1266.00

If Applicant has small entity status under 37 CFR 1.9 and 1.27, then divide total fee by 2 and enter amount here

SMALL ENTITY  
TOTAL \$633.00

- ☒ The Commissioner is hereby authorized to charge \$633.00 to cover the payment of the filing fee to our **Deposit Account No. 03-0075** (duplicate attached).
- ☒ The Commissioner is hereby authorized to charge any deficiency in the payment of the required fee(s) or credit any overpayment to our **Deposit Account No. 03-0075**.
- ☐ Charge the issue fee set in 37 CFR 1.18 at the mailing of the Notice of Allowance, pursuant to 37 CFR (1.311(b)).

  
 David M. Tener, Esq.  
 CAESAR, RIVISE, BERNSTEIN,  
 COHEN & POKOTILOV, LTD.  
 12<sup>th</sup> Floor - 7 Penn Center /1635 Market Street  
 Philadelphia, PA 19103-2212 (215) 567-2010

Date

Sept. 19, 2000

(2-92)

Patent and Trademark Office; U.S. Department of Commerce

Applicants : Glen H. Erikson and Jasmine I. Daksis  
Invention : QUADRUPLEX DNA AND DUPLEX PROBE SYSTEMS

---

This is a patent application which includes the following:

1. Transmittal letter in duplicate
2. Drawings – 5 sheets
3. Specification – 36 pages
4. 52 Claims
5. Abstract – 1 page
6. Declaration for Patent Application -- 1 pages
7. Verified Statement Claiming Small Entity Status–  
(37 CFR 1.9(f) & 1.27 (b)) - Independent Inventor
8. Verified Statement Claiming Small Entity Status–  
(37 CFR 1.9(f) & 1.27 (c)) - Small Business Concern
9. Assignment of Glen H. Erikson and Jasmine I. Daksis  
and Recordation Sheet
10. Sequence Listing (Paper and CRF)
11. Return Receipt Postcard

“Express Mail” Mailing Label No. EL 618129273 US

Date of Deposit **September 19, 2000**

I hereby certify that the above-identified documents  
are being deposited with the United States Postal  
Service “Express Mail Post Office to Addressee”  
service under 37 CFR 1.10 on the date indicated above  
and are addressed to the Commissioner for Patents,  
Washington, D.C. 20231

  
\_\_\_\_\_  
Judith Perez

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(b))—INDEPENDENT INVENTOR**

Docket Number (Optional)

E1047/20044

Applicant, Patentee, or Identifier: Glen H. Erikson et al.

Application or Patent No.: \_\_\_\_\_

Filed or Issued: \_\_\_\_\_

Title: Quadruplex DNA and Duplex Probe Systems

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ No such person, concern, or organization exists.  
☒ Each such person, concern, or organization is listed below.

Ingeneus Corporation  
Trident House  
Broad Street  
Bridgetown Barbados

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

Glen H. Erikson

Jasmine I. Daksis

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of inventor

Signature of inventor

Signature of inventor

Date

Date

Date

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN

Docket Number (Optional)  
E1047/20044

Applicant or Patentee: Glen H. Erikson and Jasmine I. Daksis  
Serial or Patent No.: \_\_\_\_\_  
Filed or Issued: \_\_\_\_\_  
Title: Quadruplex DNA and Duplex Probe Systems

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Ingeneus Corporation  
ADDRESS OF SMALL BUSINESS CONCERN Trident House, Broad Street, Bridgetown, Barbados

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.  
☐ each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)


I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Glen H. Erikson

TITLE OF PERSON IF OTHER THAN OWNER \_\_\_\_\_

ADDRESS OF PERSON SIGNING Providenciales, Turks and Caicos Islands, British West Indies

SIGNATURE  DATE 15 Sept 2000

Variable	Mean	SD	Min	Max
Age	35.2	12.5	18	65
Gender	0.45	0.50	0	1
Marital Status	0.60	0.49	0	1
Education	12.5	2.1	9	16
Income	3500	1500	1000	8000
Health Status	0.75	0.43	0	1
Exercise Frequency	0.30	0.48	0	1
Stress Level	0.65	0.47	0	1
Sleep Quality	0.55	0.50	0	1
Dietary Habits	0.40	0.50	0	1
Work-Life Balance	0.50	0.50	0	1
Family Support	0.70	0.46	0	1
Community Involvement	0.35	0.48	0	1
Personal Growth	0.60	0.49	0	1
Life Satisfaction	0.70	0.46	0	1
Overall Well-being	0.65	0.47	0	1

5

10

15

20

25

SPECIFICATION

BACKGROUND OF THE INVENTION

1. Field of Invention

5 The invention relates to nucleic acid multiplexes, and more particularly to methods wherein quadruplexes are formed by specific binding between double-stranded nucleic acid probes and double-stranded nucleic acid target sequences.

2. Description of Related Art

10 Although nucleic acid duplexes are the most widely studied type of multiple-strand nucleic acid structures, it has been discovered that nucleic acids also form triplex and quadruplex structures under certain conditions.

15 Until recently, hybridization among three nucleic acid strands to form a triplex was widely believed to be confined to very limited species of nucleic acids (e.g., polypurine or polypyrimidine sequences). See, e.g., Floris et al., "Effect of cations on purine-purine-pyrimidine triple helix formation in mixed-valence salt solutions," 20 260 Eur. J. Biochem. 801-809 (1999). Moreover, triplex formation or hybridization was thought to be based on Hoogsteen binding between limited varieties of adjacent nucleobases, rather than Watson-Crick base pairing. See, e.g., Floris et al. and U.S. Patent No. 5,874,555 to Dervan et al. However, the inventors have recently disclosed in 25 several patent applications that triplex nucleic acids based on Watson-Crick base pairing can be created and used as the basis for a highly accurate and sensitive assay for specific binding. See U.S. Patent Applications Nos. 30 09/613,263 and 09/468,679, respectively filed July 10, 2000 and December 21, 1999.

As was the case with triplex nucleic acids, the conventional wisdom regarding quadruplex nucleic acids has

been that such peculiar structures only exist under relatively extreme conditions for a relatively narrow class of nucleic acids. In particular, Sen et al. (Nature 334:364-366 (1988)) disclosed that guanine-rich oligonucleotides can spontaneously self-assemble into four-stranded helices *in vitro*. Sen et al. (Biochemistry 31:65-70 (1992)) disclosed that these four-stranded complexes can further associate into superstructures composed of 8, 12, or 16 oligomers.

Marsh et al. (Biochemistry 33:10718-10724 (1994), and Nucleic Acids Research 23:696-700 (1995)) disclosed that some guanine-rich oligonucleotides can also assemble in an offset, parallel alignment, forming long "G-wires". These higher-order structures are stabilized by G-quartets that consist of four guanosine residues arranged in a plane and held together through Hoogsteen base pairings. According to Sen et al. (Biochemistry 31:65-70 (1992)), at least three contiguous guanines within the oligomer are critical for the formation of these higher order structures.

It has been suggested that four-stranded DNAs play a role in a variety of biological processes, such as inhibition of HIV-1 integrase (Mazumder et al., Biochemistry 35:13762-13771 (1996)), formation of synapsis during meiosis (Sen et al., Nature 334:364-366 (1988)), and telomere maintenance (Williamson et al., Cell 59:871-880 (1989)); Baran et al., Nucleic Acids Research 25:297-303 (1997)).

It has been further suggested that controlling the production of guanine-rich quadruplexes might be the key to controlling such biological processes. For example, U.S. Patent No. 6,017,709 to Hardin et al. suggests that telomerase activity might be controlled through drugs that inhibit the formation of guanine quartets.

U.S. Patent No. 5,888,739 to Pitner et al. discloses that G-quartet based quadruplexes can be employed in an assay for detecting nucleic acids. Upon hybridization to a complementary oligonucleotide, the G-quartet structure unfolds or linearizes, thereby increasing the distance between a donor and an acceptor on different parts of the G-quartet structure, resulting in a decrease in their interaction and a detectable change in a signal (e.g., fluorescence) emitted from the structure.

U.S. Patent No. 5,912,332 to Agrawal et al. discloses a method for the purification of synthetic oligonucleotides, wherein the synthetic oligonucleotides hybridize specifically with a desired, full-length oligonucleotide and concomitantly form a multimer aggregate, such as quadruplex DNA. The multimer aggregate containing the oligonucleotide to be purified is then isolated using size-exclusion techniques.

Despite the foregoing developments, the full potential of quadruplex nucleic acid has neither been fully appreciated nor fully exploited.

All references cited herein are incorporated herein by reference in their entireties.

#### SUMMARY OF THE INVENTION

The invention provides a multiplex structure comprising: a first strand containing a first sequence of nucleobases; a second strand containing a second sequence of nucleobases, wherein the second strand is associated with the first strand by Watson-Crick bonding; a third strand containing a third sequence of nucleobases; and a fourth strand containing a fourth sequence of nucleobases, wherein the fourth strand is associated with the second strand and the third strand by Watson-Crick bonding.



Also provided is a method for providing the multiplex structure of the invention. The method comprises: providing a hybridization medium comprising the first strand, the second strand, the third strand, the fourth strand, water, a buffer and at least one promoter; and incubating the hybridization medium for an incubation time effective to hybridize the second strand to the fourth strand to provide the multiplex structure.

Still further provided is an assay for single-stranded and double-stranded targets employing a double-stranded probe.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described in conjunction with the following drawings in which like reference numerals designate like elements and wherein:

Figs. 1, 2, 3, 4 and 5 are composite graphs of fluorescent intensity plotted as a function of wavelength for each sample analyzed.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Unlike the quadruplexes discussed in the Background Section above, the preferred multiplex structures of the invention contain at least four strands of nucleic acid bonded together according to traditional Watson-Crick bonding rules.

As used herein, the term "Watson-Crick bonding" is intended to define specific association between opposing pairs of nucleic acid (and/or nucleic acid analogue) strands via matched, opposing bases. While the formation of a Watson-Crick quadruplex may sometimes be referred to as a hybridization event herein, that is merely for convenience and is not intended to limit the scope of the invention with respect to how the formation of a Watson-Crick quadruplex can be best characterized.

The multiplex structures of the invention are preferably quadruplexes. Each strand of the multiplex independently comprises a nucleic acid or a nucleic acid analogue. Suitable nucleic acids include, e.g., DNA or RNA. Preferred nucleic acid analogues contain an uncharged or partially charged backbone (i.e., a backbone having a charge that is not as negative as a native DNA backbone).

In certain embodiments, one of the second and fourth strands of the four-stranded quadruplex comprises DNA and the other of the second and fourth strands comprises RNA, mRNA, hnRNA, rRNA, tRNA or cDNA.

In certain embodiments, the second strand and the fourth strand are anti-parallel to each other. These embodiments are defined as having mirror complementarity. In these embodiments, a major groove of the first and second strands is placed in a major groove of the third and fourth strands.

In other embodiments, the second and fourth strands are parallel to each other. In these embodiments, which possess "nested complementarity," a major groove of the first and second strands is placed in a minor groove of the third and fourth strands.

In certain embodiments, each nucleobase binds to no more than two other nucleobases. In some of these embodiments, the bases of the second strand specifically bond (via Watson-Crick rules) to the matching bases of the first strand and to the matching bases of the fourth strand, and the bases of the fourth strand specifically bond (via Watson-Crick rules) to the matching bases of the third strand and to the matching bases of the second strand, wherein the bases of the first and third strands bind to no more than one other base each. Thus, in addition to the traditional Watson-Crick base pairs, such

embodiments include the following Watson-Crick base triplets: A-T-A, T-A-T, U-A-T, T-A-U, A-U-A, U-A-U, G-C-G and/or C-G-C (including C<sup>+</sup>-G-C, and/or any other ionized species of base).

5 In certain embodiments, it is believed that opposing bases of the first and third strands also bind to each other, in addition to: (a) the binding between opposing bases of the first and second strands; (b) the binding between opposing bases of the third and fourth strands; and  
10 (c) the binding between opposing bases of the second and fourth strands.

In certain embodiments of the multiplex structure of the invention, no strand is contiguous with another strand. That is, there are at least four separate strands.  
15 Although folded conformations and the like (e.g., hairpin turns, etc.) are within the scope of the invention, folded portions of a single strand do not make the strand count more than once toward the minimum of four separate strands.

Multiplex structures of the invention preferably do not rely on Hoogsteen bonding or G-G quartets for maintenance of the multiplex structure, although insignificant amounts of Hoogsteen bonding and/or G-G quartets may be present. That is, multiplex structures of the invention are preferably substantially free of  
20 Hoogsteen bonding, and substantially free of G-G quartets.

In certain embodiments, the first and second strands of the multiplex are 5 to 50 bases long (more preferably 5 to 30 bases long) and the third and fourth strands are 8 to 3.3 X 10<sup>9</sup> base pairs long. For example, the first and  
25 second strands can constitute a double-stranded probe and the third and fourth strands can constitute a double-stranded target, such as genomic DNA, which can contain a haplotype.

In embodiments, the third strand and the fourth strand are PCR amplified products.

The multiplexes of the invention can be present in solution, on a solid support, *in vitro* or *in vivo*. The solid support can be electrically conductive (e.g., an electrode) or non-conductive.

Quadruplex formation according to the invention is suitable for a variety of uses. For example, double-stranded probes covalently bound to a double-stranded nucleic acid cleaving agent can be used to specifically cleave target sequences of double-stranded nucleic acids. Double-stranded probes covalently bound to a chemotherapeutic agent can be used to specifically treat target sequences of double-stranded nucleic acids. Thus, the invention encompasses multiplex structures further comprising a therapeutic, prophylactic or diagnostic agent bound to at least one of the first, second, third and fourth strands.

In addition, multiplexes of the invention are suitable for use in nanoengineering, such as to provide electrical circuitry on a molecular (i.e., nanoscale) level. Further details regarding nanoengineering with nucleic acids can be found in U.S. Patent No. 5,948,897 to Sen et al. and the references cited therein.

Multiplex structures of the invention can be provided by a method comprising: providing a hybridization medium comprising the first strand, the second strand, the third strand, the fourth strand, water, a buffer and a promoter; and incubating the hybridization medium for an incubation time effective to hybridize the second strand to the fourth strand.

The hybridization medium can include any conventional medium known to be suitable for preserving nucleotides.

See, e.g., Sambrook et al., "Molecular Cloning: A Lab Manual," Vol. 2 (1989). For example, the medium can comprise nucleotides, water, buffers and standard salt concentrations. When divalent cations are used exclusively to promote quadruplex formation, chelators such as EDTA or EGTA should not be included in the reaction mixtures.

Specific binding between complementary bases occurs under a wide variety of conditions having variations in temperature, salt concentration, electrostatic strength, and buffer composition. Examples of these conditions and methods for applying them are known in the art.

Unlike many Hoogsteen-type multiplexes, which are unstable or non-existent at pH levels above about 7.6, the Watson-Crick multiplexes of the invention are stable over a wide range of pH levels, preferably from about pH 5 to about pH 9.

Moreover, the inventive multiplexes do not require the presence of homopyrimidine sequences or homopurine sequences, as in certain prior art quadruplexes. For example, the target sequence can contain 25% to 75% purine bases and 75% to 25% pyrimidine bases in any order.

It is preferred that multiplexes be formed at a temperature of about 5°C to about 25°C for about two hours or less. The incubation time is preferably less than five minutes, even at room temperature. Longer reaction times are not required, but incubation for up to 24 hours in most cases did not adversely affect the quadruplexes. The fast binding times of Watson-Crick quadruplexes of the invention contrast with the much longer binding times for Hoogsteen quadruplexes.

The promoter in the hybridization medium is preferably an intercalating agent or a cation. The intercalating agent can be, e.g., a fluorophore, such as a member

selected from the group consisting of YOYO-1, TOTO-1, ethidium bromide, ethidium homodimer-1, ethidium homodimer-2 and acridine.

Suitable cations include, e.g., monovalent cations, such as  $\text{Na}^+$  (preferably at a concentration of 50mM to 125mM),  $\text{K}^+$ , and other alkali metal ions; divalent cations, such as alkaline earth metal ions (e.g.,  $\text{Mg}^{+2}$  and  $\text{Ca}^{+2}$ ) and divalent transition metal ions (e.g.,  $\text{Mn}^{+2}$ ,  $\text{Ni}^{+2}$ ,  $\text{Cd}^{+2}$ ,  $\text{Co}^{+2}$  and  $\text{Zn}^{+2}$ ); and cations having a positive charge of at least three, such as  $\text{Co}(\text{NH}_3)_6^{+3}$ , trivalent spermidine and tetravalent spermine.  $\text{Mn}^{+2}$  is preferably provided at a concentration of 10mM to 30mM.  $\text{Mg}^{+2}$  is preferably provided at a concentration of 15mM to 20mM.  $\text{Ni}^{+2}$  is preferably provided at a concentration of about 20mM. In embodiments,  $\text{Mg}^{+2}$  and  $\text{Mn}^{+2}$  are provided in combination at a concentration of 10mM each, 15mM each, 20mM each, 25mM each or 30mM each (i.e., 10-30 mM each).

The amount of cation added to the medium in which the multiplex forms depends on a number of factors, including the nature of the cation, the concentration of probe, the concentration of target, the presence of additional cations and the base content of the probe and target. The preferred cation concentrations and mixtures can routinely be discovered experimentally.

Although not required, other promoters include, e.g., single stranded binding proteins such as Rec A protein, T4 gene 32 protein, E. coli single stranded binding protein, major or minor nucleic acid groove binding proteins, viologen and additional intercalating substances such as actinomycin D, psoralen, and angelicin. Such facilitating reagents may prove useful in extreme operating conditions, for example, under abnormal pH levels or extremely high temperatures.

5 The invention also enables a method in which hybridization of the second strand to the fourth strand inactivates an activity associated with at least one of the third strand and the fourth strand. Thus, at least one of the first strand and the second strand further comprises a pharmaceutical agent, wherein hybridization of the second strand to the fourth strand places the pharmaceutical agent an effective distance from a target on the third strand, the fourth strand or on another molecule associated with at least one of the third strand and the fourth strand. The pharmaceutical agent is preferably a member selected from the group consisting of nucleic acids designed to bind promoter sequences of clinically relevant genes, nucleic acids designed to bind clinically relevant genes, or 10 nucleic acids designed to bind origin of replication sites of pathogens.

15 In preferred embodiments, the invention provides a rapid, sensitive, environmentally friendly, and safe method for assaying binding between a single-stranded or double-stranded target and a double-stranded probe, wherein the target comprises a nucleic acid sequence or a nucleic acid analogue sequence and the probe comprises a nucleic acid sequence or a nucleic acid analogue sequence.

20 The inventive assay can be used to, e.g., identify accessible regions in folded nucleotide sequences, to determine the number of mismatched base pairs in a hybridization complex, and to map genomes.

25 The invention not only detects the presence of specific probe-target binding, but also provides qualitative and quantitative information regarding the nature of interaction between a probe and target. Thus, the invention enables the practitioner to distinguish among a perfect match, a one base pair mismatch, a two base pair 30

mismatch, a three base pair mismatch, a one base pair deletion, a two base pair deletion and a three base pair deletion arising between a sequence in the double-stranded probe and in a sequence in the double-stranded target.

5           Embodiments of the invention comprise calibrating the measured signal (e.g., fluorescence, chemiluminescence, electrochemiluminescence or electrical properties) for a first probe-target mixture against the same type of signal exhibited by other probes combined with the same target, 10 wherein each of the other probes differs from the first probe by at least one base.

          A calibration curve can be generated, wherein the magnitude of the measured signal (e.g., fluorescent intensity) is a function of the binding affinity between 15 the target and probe. As the binding affinity between the target and a plurality of different probes varies with the number of mismatched bases, the nature of the mismatch(es) (A-G vs. A-C vs. T-G vs. T-C, etc.), the location of the mismatch(es) within the quadruplex, etc., the assay of the 20 invention can be used to sequence the target.

          In embodiments, the signal measured can be the fluorescent intensity of a fluorophore included in the test sample. In such embodiments, the binding affinity between 25 the probe and target can be directly or inversely correlated with the intensity, depending on whether the fluorophore signals hybridization through signal quenching or signal amplification. Under selected conditions, the fluorescent intensity generated by intercalating agents can be directly correlated with probe-target binding affinity, 30 whereas the intensity of preferred embodiments employing a non-intercalating fluorophore covalently bound to the probe can be inversely correlated with probe-target binding affinity. The fluorescent intensity decreases for non-



intercalating fluorophores as the extent of matching between the probe and target increases, preferably over a range inclusive of 0-2 mismatches and/or deletions, more preferably over a range inclusive of 0-3 mismatches and/or deletions.

The invention enables quantifying the binding affinity between probe and target. Such information can be valuable for a variety of uses, including designing antisense drugs with optimized binding characteristics.

The assay of the invention is preferably homogeneous. The assay can be conducted without separating the probe-target complex from the free probe and free target prior to detecting the magnitude of the measured signal. The assay does not require a gel separation step, thereby allowing a great increase in testing throughput. Quantitative analyses are simple and accurate. Consequently the binding assay saves a lot of time and expense, and can be easily automated. Furthermore, it enables binding variables such as buffer, pH, ionic concentration, temperature, incubation time, relative concentrations of probe and target sequences, intercalator concentration, length of target sequences, length of probe sequences, and possible cofactor (i.e., promoter) requirements to be rapidly determined.

The assay can be conducted in, e.g., a solution within a well or microchannel, on an impermeable surface or on a biochip. In certain embodiments, the third and fourth strands are provided in the hybridization medium before the first and second strands, and the first and second strands are provided in dehydrated form prior to rehydration by contact with the hybridization medium.

Moreover, the inventive assay is preferably conducted without providing a signal quenching agent on the target or on the probe.

Although the inventors have previously disclosed the advantages of fluorescent intensity assays for hybridization (see, e.g., U.S. Patent Application No. 09/224,505, filed December 31, 1998), certain embodiments of the inventive assay specifically detect quadruplexes of the probe and the double-stranded target, thus obviating the need to denature the target. It is surprising that the inventors have been able to specifically assay quadruplexes formed between double-stranded probes and double-stranded targets, wherein the interaction between the probes and targets is based on Watson-Crick base pairing (at least in the sense that A binds to T (or U, in the case of RNA) and G binds to C), rather than the very limited Hoogsteen model of quadruplex hybridization of, e.g., Pitner et al., *supra*.

Suitable probes for use in the inventive assay include, e.g., dsDNA, dsRNA, DNA:RNA hybrids, dsPNA, PNA:DNA hybrids and other double-stranded nucleic acid analogues having uncharged or partially-charged backbones. Probe sequences having any length from 8 to 20 bases are preferred since this is the range within which the smallest unique DNA sequences of prokaryotes and eukaryotes are found. Probes of 12 to 18 bases are particularly preferred since this is the length of the smallest unique sequences in the human genome. In embodiments, probes of 5 to 30 bases are most preferred. However, a plurality of shorter probes can be used to detect a nucleotide sequence having a plurality of non-unique target sequences therein, which combine to uniquely identify the nucleotide sequence. The length of the probe can be selected to match the length of the target.

5 The instant invention does not require the use of radioactive probes, which are hazardous, tedious and time-consuming to use, and need to be constantly regenerated. Probes of the invention are preferably safe to use and stable for years. Accordingly, probes can be made or ordered in large quantities and stored.

10 In embodiments, the probe is labeled with a multi-molecule signaling complex or a redox pair, or with a label that elicits chemiluminescent or electrochemiluminescent properties.

15 When a fluorescent intercalator is not present in the hybridization medium, it is preferred that the probe or target (preferably the probe) have a fluorescent label covalently bound thereto. The label is preferably a non-intercalating fluorophore or an intercalating fluorophore. In such embodiments, the fluorophore is preferably bound to the probe at either end. Preferred fluorescent markers include biotin, rhodamine, acridine and fluorescein, and other markers that fluoresce when  
20 irradiated with exciting energy.

25 The excitation wavelength is selected (by routine experimentation and/or conventional knowledge) to correspond to this excitation maximum for the fluorophore being used, and is preferably 200 to 1000 nm. Fluorophores are preferably selected to have an emission wavelength of 200 to 1000 nm. In preferred embodiments, an argon ion laser is used to irradiate the fluorophore with light having a wavelength in a range of 400 to 540 nm, and fluorescent emission is detected in a range of 500 to 750  
30 nm.

The assay of the invention can be performed over a wide variety of temperatures, such as, e.g., from 5 to 85°C. Certain prior art assays require elevated temperatures,

adding cost and delay to the assay. On the other hand, the invention can be conducted at room temperature or below (e.g., at a temperature below 25°C).

5 The reliability of the invention is independent of guanine and cytosine content in said target. Since G-C base pairs form three hydrogen bonds, while A-T base pairs form only two hydrogen bonds, target and probe sequences with a higher G or C content are more stable, possessing higher melting temperatures. Consequently, base pair mismatches that increase the GC content of the hybridized probe and target region above that present in perfectly matched hybrids may offset the binding weakness associated with a mismatched probe.

10 The inventive assay is extremely sensitive, thereby obviating the need to conduct PCR amplification of the target. For example, it is possible to assay a test sample having a volume of about 20 microliters, which contains about 10 femtomoles of target and about 10 femtomoles of probe. Embodiments of the invention are sensitive enough to assay targets at a concentration of  $5 \times 10^{-9}$  M, preferably at a concentration of not more than  $5 \times 10^{-10}$  M. Embodiments of the invention are sensitive enough to employ probes at a concentration of  $5 \times 10^{-9}$  M, preferably at a concentration of not more than  $5 \times 10^{-10}$  M. It should go without saying that the foregoing values are not intended to suggest that the method cannot detect higher concentrations.

25 The ratio of probe (e.g., first and second strands) to target (e.g., third and fourth strands) is 30:1 to 1:1, preferably about 10:1.

30 The invention will be illustrated in more detail with reference to the following Examples, but it should be understood that the present invention is not deemed to be limited thereto.

EXAMPLESExample 1

Sense and antisense 50-mer ssDNA target sequences, derived from exon 10 of the human cystic fibrosis gene (Nature 380, 207 (1996)) and modified such that the percent GC content was changed from 30% to 52%, were synthesized on a DNA synthesizer (Expedite 8909, PerSeptive Biosystems) and purified by HPLC. Equimolar amounts of complementary oligonucleotides were denatured at 95°C for 10 minutes and allowed to anneal gradually as the temperature cooled to 21°C over 1.5 hours. DsDNA oligonucleotides were dissolved in ddH<sub>2</sub>O at a concentration of 1 pmole/μl.

Sequence for the sense strand (SEQ ID NO:1) of the wild-type dsDNA Target A: 5'-GAG CAC CAT GAC AGA CAC TGT CAT CTC TGG TGT GTC CTA CGA TGA CTC TG-3'.

Sequence for the antisense strand (SEQ ID NO:2) of the wild-type dsDNA Target A: 5'-CAG AGT CAT CGT AGG ACA CAC CAG AGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Target B was a 50-mer mutant dsDNA target identical to the wild-type target DNA except for a one base pair mutation (underlined) on the sense and antisense strands, wherein the wild-type bases CAT and ATG were replaced by bases CGT and ACG, respectively.

Sequence for the sense strand (SEQ ID NO:3) of mutant Target B: 5'-GAG CAC CAT GAC AGA CAC TGT CGT CTC TGG TGT GTC CTA CGA TGA CTC TG-3'.

Sequence for the antisense strand (SEQ ID NO:4) of mutant Target B: 5'-CAG AGT CAT CGT AGG ACA CAC CAG AGA CGA CAG TGT CTG TCA TGG TGC TC-3'.

Target C was a 50-mer mutant dsDNA target identical to the wild-type target DNA except for a one base pair mutation (underlined) on the sense and antisense strands,

wherein the wild-type bases CAT and ATG were replaced by bases CTT and AAG, respectively.

Sequence for the sense strand (SEQ ID NO:5) of mutant Target C: 5'-GAG CAC CAT GAC AGA CAC TGT CTT CTC TGG TGT GTC CTA CGA TGA CTC TG-3'.

Sequence for the antisense strand (SEQ ID NO:6) of mutant Target C: 5'-CAG AGT CAT CGT AGG ACA CAC CAG AGA AGA CAG TGT CTG TCA TGG TGC TC-3'.

Target D was a 50-mer mutant dsDNA target identical to the wild-type DNA except for a one base pair mutation (underlined) on the sense and antisense strands, wherein the wild-type bases CTC and GAG were replaced by bases CTT and AAG, respectively.

Sequence for the sense strand (SEQ ID NO:7) of mutant Target D: 5'-GAG CAC CAT GAC AGA CAC TGT CAT CTT TGG TGT GTC CTA CGA TGA CTC TG-3'.

Sequence for the antisense strand (SEQ ID NO:8) of mutant Target D: 5'-CAG AGT CAT CGT AGG ACA CAC CAA AGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Target E was a 50-mer mutant dsDNA target identical to the wild-type DNA except for a one base pair mutation (underlined) on the sense and antisense strands, wherein the wild-type bases CTC and GAG were replaced by bases CCC and GGG, respectively.

Sequence for the sense strand (SEQ ID NO:9) of mutant Target E: 5'-GAG CAC CAT GAC AGA CAC TGT CAT CCC TGG TGT GTC CTA CGA TGA CTC TG-3'.

Sequence for the antisense strand (SEQ ID NO:10) of mutant Target E: 5'-CAG AGT CAT CGT AGG ACA CAC CAG GGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Probe A was a 15-mer dsDNA probe with an attached fluorescein moiety at each 5' position and was designed to be mirror complementary to 15 nucleotide segments of the

sense strand and antisense strand near the center of the 50-mer wild-type Target A. The strands of the probe were synthesized on the DNA synthesizer mentioned above and purified by HPLC. Equimolar amounts of the probe strands were denatured at 95°C for 10 min and allowed to anneal as the temperature cooled to 21°C over 1.5 hours. DsDNA probe was dissolved in ddH<sub>2</sub>O at a concentration of 1 pmole/μl.

Sequence for the sense strand (SEQ ID NO:11) of Probe A: 5'-Flu-CTG TCA TCT CTG GTG-3'.

Sequence for the antisense strand (SEQ ID NO:12) of Probe A: 5'-Flu-CAC CAG AGA TGA CAG-3'.

Each hybridization reaction mixture (40μl) contained the following: 0.4 pmoles of target dsDNA, 4 pmoles of 5'-fluorescein labeled dsDNA probe, 10 mM Tris-HCl, pH 7.5 and 100 mM KCl. The reaction mixtures were incubated at room temperature (21°C) for 1 hour, without prior denaturation. Samples were placed into a quartz cuvette, irradiated with an argon ion laser beam having a wavelength of 488 nm and monitored for fluorescent emission. The maximum fluorescent intensities occurred at a wavelength of 525 nm, the emission wavelength for fluorescein. Fig. 1 shows the intensity of fluorescence plotted as a function of wavelength for each sample analyzed.

In the absence of KCl, no hybridization between the dsDNA targets and the Probe A was detected, resulting in similar fluorescent intensities observed when wild-type dsDNA Target A or mutant dsDNA Target D were mixed with dsDNA Probe A or when dsDNA Probe A was present alone (data not shown).

After a 1 hour incubation at 21°C in the presence of 100 mM KCl, dsDNA target:dsDNA-F quadruplexes consisting of perfectly complementary sequences on dsDNA Target A and dsDNA Probe A formed readily, resulting in a 62% decrease

in the intensity of fluorescent emission compared to that emitted by dsDNA Probe A alone (labeled dsDNA-F) (Fig. 1). In contrast, incompletely complementary dsDNA Target D:dsDNA-F Probe A quadruplexes, containing a 1 base pair G-T mismatch, were less stable in these reaction conditions, yielding only an 18% decrease in fluorescent intensity compared to that exhibited by dsDNA Probe A alone.

The presence of monovalent cations, such as  $K^+$ , at specific concentrations was sufficient to allow quadruplex formation between dsDNA targets and dsDNA probes labeled with fluorescein in the absence of prior denaturation. Quadruplex formation occurred on the basis of Watson-Crick base pair affinities, with a measurable and significantly greater amount of quadruplex formation between fully complementary homologous duplex strands. Moreover, the reaction occurred at room temperature within just 1 hour of incubation at a ratio of probe to target of 10 to 1, using natural dsDNA. The dsDNA targets and dsDNA probe used in this example were homologous, contained 53% GC content, and did not contain homopurine or homopyrimidine stretches on any DNA strand. DNA quadruplexes formed readily despite the inferred conclusion that the formation required the duplex probe to give up its right-handed chirality. The assay of the invention was able to identify perfectly complementary dsDNA sequences and those containing a pair of mismatched bases, using dsDNA probe.

#### Example 2

The quadruplex DNA assays performed in Example 1 were facilitated by the addition of monovalent cations to the reaction mixtures. The specificity of the assay was further examined utilizing divalent cations to facilitate



quadruplex DNA formation with dsDNA targets and dsDNA-F probes possessing 53% GC content.

Each hybridization reaction mixture (40 $\mu$ l) contained the following: 0.4 pmoles of target dsDNA, 4 pmoles of 5'-fluorescein labeled dsDNA probe, 10 mM Tris-HCl, pH 7.5 and 20mM MnCl<sub>2</sub> and 20 mM MgCl<sub>2</sub>. The reaction mixtures were incubated at room temperature (21°C) for 1 hour, without prior denaturation. Samples were placed into a quartz cuvette, irradiated with an argon ion laser beam having a wavelength of 488 nm and monitored for fluorescent emission. Fig. 2 shows the intensity of fluorescence plotted as a function of wavelength for each sample analyzed.

When dsDNA-F Probe A (with a 53% GC content) was incubated with 50-mer wild-type dsDNA Target A or mutant dsDNA Target D in the presence of 20 mM MnCl<sub>2</sub> and 20 mM MgCl<sub>2</sub>, quadruplexes were formed at room temperature under non-denaturing conditions. While perfectly matched DNA quadruplexes yielded the maximum decrease in fluorescent intensity, a 34% decrease, the less favorable dsDNA:dsDNA-F quadruplexes containing a 1 bp T-G mismatch (dsDNA Target D + dsDNA Probe A) produced a fluorescent intensity that was about the same as that observed with dsDNA Probe A alone (Fig. 2).

The presence of divalent cations, such as Mn<sup>+2</sup> and Mg<sup>+2</sup>, facilitated quadruplex formation under non-denaturing conditions to allow accurate discrimination between homologous, that is mirror complementary, dsDNA target and dsDNA probe quadruplexes, and quadruplex sequences containing a pair of bases which are mismatched.

Divalent cations facilitated the formation of mirror complementary Watson-Crick quadruplexes despite the

inferred conclusion that the formation required the duplex probe to give up its right-handed chirality.

Example 3

The quadruplex DNA assays performed in Examples 1 and 2 were facilitated by the addition of either monovalent cations or divalent cations in the reaction mixtures. The next Examples demonstrate the specificity of the quadruplex DNA assays when a DNA intercalator is employed.

Probe B was a 15-mer dsDNA probe identical to probe A, without the attached fluorescein marker, and was prepared similarly.

Each hybridization reaction mixture (40  $\mu$ l) contained the following: 0.4 pmoles of dsDNA target, 4 pmoles of dsDNA Probe B, 0.5 x TBE and 100 nM of the DNA intercalator YOYO-1 (Molecular Probes, Eugene, OR, USA). The reaction mixtures were incubated at 21°C for 5 minutes and then assayed. Samples were placed into a quartz cuvette, and irradiated with an argon ion laser beam having a wavelength of 488 nm. The maximum fluorescent intensity occurred at a wavelength of 535 nm, indicative of intercalation of YOYO-1.

The fluorescent intensities observed when no target or probe was present (YOYO-1 only) are shown in Fig. 3. Fig. 3 also shows the fluorescent intensities observed when the reaction mixtures combined dsDNA Probe B with wild-type 50-mer dsDNA Target A, which contained homologous sequences, or with four other dsDNA targets which, but for one mismatched pair of bases, contained sequences which were homologous to the base sequences in the dsDNA Probe B. Homologous, that is to say mirror complementary, wild-type target dsDNA when present in the reaction mixture with the dsDNA Probe B produced the greatest fluorescent intensity. Mismatched dsDNA targets when incubated with dsDNA Probe B

in the reaction mixture yielded lesser fluorescent intensity values ranging from 20% less for dsDNA Target C to 80% less for dsDNA Target E, compared to that achieved by perfectly matched quadruplexes (Fig. 3).

5 It was observed that Watson-Crick quadruplexes, stabilized by YOYO-1 intercalation, formed more readily between dsDNA target and dsDNA probe when that probe contained perfectly homologous, that is to say mirror complementary sequences, than when there was a single pair of bases which were not homologous, that is to say not mirror complementary to sequences in the dsDNA targets. Watson-Crick quadruplexes formed readily despite the inferred conclusion that the quadruplex formation required the duplex probe to give up its right-handed chirality.

10  
15 Example 4

In this example, 50-mer dsDNA targets were exposed to the 53% GC 15-mer dsDNA Probe C, whose Watson-Crick complementarity exists between bases of the strands of the probe and bases of the strands of the target when the major groove of the duplex probe is placed in the minor groove of the duplex target, herein referred to as nested complementarity. The sequences of bases in the duplex probe are not homologous but inverted in relation to those in the duplex target.

20  
25 The strands of the probe were synthesized on the DNA synthesizer mentioned above and purified by HPLC. Equimolar amounts of the probe strands were denatured at 95°C for 10 min and allowed to anneal as the temperature cooled to 21°C over 1.5 hours. DsDNA probe was dissolved in ddH<sub>2</sub>O at a concentration of 1pmole/μl.

30 Sequence for the sense strand (SEQ ID NO:13) of dsDNA Probe C: 5'-GAC AGT AGA GAC CAC-3'.

Sequence for the antisense strand (SEQ ID NO:14) of dsDNA Probe C: 5'-GTG GTC TCT ACT GTC-3'.

Each hybridization reaction mixture (40  $\mu$ l) contained the following: 0.4 pmoles of target dsDNA, 4 pmoles of dsDNA Probe C, 0.5 x TBE and 100 nM of the DNA intercalator YOYO-1. The reaction mixtures were incubated at room temperature (21°C) for 5 minutes, placed in a quartz cuvette, and irradiated with an argon ion laser beam having a wavelength of 488 nm. The maximum fluorescent intensity occurred at a wavelength of 535 nm, indicative of intercalation of YOYO-1.

Fig. 4 illustrates that in the absence of prior denaturation, the highest fluorescent intensities were achieved when wild-type 50-mer dsDNA Target A was reacted with 15-mer dsDNA Probe C, which was a perfect match on a nested complementary basis to dsDNA Target A. The fluorescent intensity is indicative of DNA binding taking place, in this case quadruplex formation between the dsDNA target and nested complementary dsDNA probe.

Mutant dsDNA targets which were mismatched with the duplex probe by a single pair of bases when matching was assessed on the inverted homology basis of nested complementarity, formed measurably fewer quadruplex complexes with the dsDNA probe, than did the fully complementary wild-type dsDNA target. The various mismatches, which were assayed on a mirror complementary basis in Example 3 were assayed on a nested complementary basis in this example.

As shown in Fig. 4, the fluorescent intensities produced by the quadruplexes formed with the 1 bp mismatched dsDNA targets plus dsDNA Probe C, ranged from 8% to 16% less than that achieved by perfectly matched quadruplexes (dsDNA Target A + dsDNA Probe C).

Greater discrimination in fluorescence was observed between perfectly matched and mismatched quadruplexes in Example 3. This suggests that fully complementary or 1 base pair mismatched dsDNA probes prefer binding in a nested complementary orientation rather than a mirror complementary orientation to dsDNA target.

This example shows that Watson-Crick quadruplex binding between nested complementary duplex DNA readily occurs in the presence of YOYO-1. This facility arises in part from the fact that nested complementary quadruplex binding allows the right-handed chirality of each interacting duplex to be maintained.

Example 5

50-mer ssDNA target sequences, derived from exon 10 of the human cystic fibrosis gene (Nature 380, 207 (1996)) and modified such that the percent GC content was changed from 30% to 52%, were synthesized on a DNA synthesizer (Expedite 8909, PerSeptive Biosystems) and purified by HPLC.

Sequence for the strand (SEQ ID NO:2) being the 50-mer wild-type ssDNA Target F: 5'- CAG AGT CAT CGT AGG ACA CAC CAG AGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Target G was a 50-mer mutant ssDNA target identical to wild-type ssDNA Target F except for a one base mutation (underlined).

Sequence for the strand (SEQ ID NO:4) of mutant ssDNA Target G: 5'- CAG AGT CAT CGT AGG ACA CAC CAG AGA CGA CAG TGT CTG TCA TGG TGC TC-3'.

Target H was a 50-mer mutant ssDNA target identical to wild-type ssDNA Target F except for a one base mutation (underlined).

Sequence for the strand (SEQ ID NO:6) of mutant ssDNA Target H: 5'- CAG AGT CAT CGT AGG ACA CAC CAG AGA AGA CAG TGT CTG TCA TGG TGC TC-3'.

Target I was a 50-mer mutant ssDNA target identical to wild-type ssDNA Target F except for a one base mutation (underlined).

Sequence for the strand (SEQ ID NO:8) of mutant ssDNA Target I: 5'- CAG AGT CAT CGT AGG ACA CAC CAA AGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Target J was a 50-mer mutant ssDNA target identical to wild-type ssDNA Target F except for a one base mutation (underlined).

Sequence for the strand (SEQ ID NO:10) of mutant ssDNA Target J: 5'-CAG AGT CAT CGT AGG ACA CAC CAG GGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Target K was a 50-mer mutant ssDNA target identical to wild-type ssDNA Target F except for a one base mutation (underlined).

Sequence for the strand (SEQ ID NO:15) of mutant ssDNA Target K: 5'-CAG AGT CAT CGT AGG ACA CAC CAG CGA TGA CAG TGT CTG TCA TGG TGC TC-3'.

Probe B was a 15-mer dsDNA probe identical to Probe A without the fluorescein marker, and was prepared accordingly. One of the strands of Probe B (i.e., SEQ ID NO:11) was complementary to a 15 nucleotide segment near the center of 50-mer wild-type ssDNA Target F.

Each hybridization reaction mixture (40µl) contained the following: 0.4 pmoles of target ssDNA, 4 pmoles of dsDNA probe, 0.5 x TBE and 100 nM YOYO-1. The reaction mixtures were incubated at room temperature (21°C) for 5 minutes, without prior denaturation. Samples were placed into a quartz cuvette, irradiated with an argon ion laser beam having a wavelength of 488 nm and monitored for fluorescent emission. Integration time of all laser irradiation was 80 msec. The maximum fluorescent intensities occurred at a wavelength of 535 nm, indicative

of intercalation of YOYO-1. Fig. 5 shows the intensity of fluorescence plotted as a function of wavelength for each sample analyzed.

5 In the absence of target ssDNA, some hybridization between the dsDNA probes occurred on a mirror complementary basis (Fig. 5). Such binding between homologous duplex DNA is disclosed in prior examples. SsDNA targets incubated alone with YOYO-1 resulted in low intensity emission values, which were less than one-half the value of the intensity emission of the dsDNA probes alone incubated with  
10 YOYO-1 (data not shown).

After a 5 minute incubation at 21°C in the presence of 100mM YOYO-1, ssDNA Target F readily formed binding complexes with perfectly complementary sequences on dsDNA  
15 Probe B, resulting in a 79% increase in the intensity of fluorescent emission compared to that emitted by dsDNA Probe B alone (Fig 5). In contrast, incompletely complementary ssDNA targets containing various one base pair mismatches were less stable in these reaction  
20 conditions, yielding only a 19% to 31% increase in fluorescent intensity compared to that exhibited by dsDNA Probe B alone (Fig. 5).

The presence of YOYO-1, an intercalator, was sufficient to allow binding between dsDNA probes and ssDNA  
25 targets in the absence of prior denaturation. Binding occurred on the basis of Watson-Crick base pair affinities, with a measurable and significantly greater amount of binding between fully complementary strands. The reaction occurred at room temperature within just 5 minutes of  
30 incubation at a ratio of probe to target of 10 to 1, using natural DNA. The ssDNA targets and dsDNA probe used in this example contained 53% GC content and did not contain homopurine or homopyrimidine stretches on any DNA strand.

The assay of the invention was able to identify perfectly complementary ssDNA sequences and those containing mismatched bases, using dsDNA probes.

5 The assay of the invention functioned notwithstanding that binding occurred to a substantial extent between duplex probes which were fully self-complementary, i.e., of homologous strand sequence and which bound to one another in a mirror complementary fashion, that is to say major groove to major groove.

10 While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.



CLAIMS

WHAT IS CLAIMED IS:

1. A multiplex structure comprising:

a first strand containing a first sequence of  
nucleobases;

a second strand containing a second sequence of  
nucleobases, wherein said second strand is  
associated with said first strand by Watson-Crick  
bonding;

a third strand containing a third sequence of  
nucleobases; and

a fourth strand containing a fourth sequence of  
nucleobases, wherein said fourth strand is  
associated with said second strand and said third  
strand by Watson-Crick bonding.

2. The multiplex structure of claim 1, wherein said  
multiplex structure is an isolated, purified, artificial or  
synthetic quadruplex.

3. The multiplex structure of claim 1, wherein each  
said strand independently comprises a nucleic acid or a  
nucleic acid analogue.

4. The multiplex structure of claim 3, wherein each  
said strand independently comprises DNA or RNA.

5. The multiplex structure of claim 3, wherein each  
said strand independently comprises a nucleic acid analogue  
containing an uncharged or partially charged backbone.

6. The multiplex structure of claim 1, wherein one  
of said second strand or said fourth strand comprises DNA  
and the other of said second strand or said fourth strand  
comprises RNA, mRNA, hnRNA, rRNA, tRNA or cDNA.

7. The multiplex structure of claim 1, wherein said  
second strand and said fourth strand are anti-parallel to  
each other.

8. The multiplex structure of claim 7, wherein a major groove of said first strand and said second strand is placed in a major groove of said third strand and said fourth strand.

5 9. The multiplex structure of claim 1, wherein said second strand and said fourth strand are parallel to each other.

10 10. The multiplex structure of claim 9, wherein a major groove of said first strand and said second strand is placed in a minor groove of said third strand and said fourth strand.

11. The multiplex structure of claim 1, wherein each nucleobase binds to no more than two other nucleobases.

15 12. The multiplex structure of claim 1, wherein no strand is contiguous with another strand.

13. The multiplex structure of claim 1, wherein said multiplex structure is substantially free of Hoogsteen bonding.

20 14. The multiplex structure of claim 1, wherein said multiplex structure is substantially free of G-G quartets.

15. The multiplex structure of claim 1, wherein said first strand and said second strand are 5 to 50 base pairs long.

25 16. The multiplex structure of claim 1, wherein said third strand and said fourth strand are genomic DNA.

17. The multiplex structure of claim 1, wherein said third strand and said fourth strand include a haplotype in genomic DNA.

30 18. The multiplex structure of claim 1, wherein said third strand and said fourth strand are PCR amplified products.

19. The multiplex structure of claim 1, wherein said multiplex structure is free of solid support.

20. The multiplex structure of claim 1, wherein said multiplex structure is bound to a solid support.

21. The multiplex structure of claim 1, wherein said solid support is not electrically conductive.

5 22. The multiplex structure of claim 1, wherein said solid support is electrically conductive.

23. The multiplex structure of claim 1, further comprising a therapeutic, prophylactic or diagnostic agent bound to at least one of said first strand, said second strand, said third strand and said fourth strand.

10 24. The multiplex structure of claim 1, wherein said first strand and said second strand are each 5 to 30 bases long and said third strand and said fourth strand are each 8 to  $3.3 \times 10^9$  base pairs long.

15 25. The multiplex structure of claim 1, wherein said fourth sequence contains 25% to 75% purine bases and 75% to 25% pyrimidine bases in any order.

26. A method for providing the multiplex structure of claim 1, said method comprising:

20 providing a hybridization medium comprising said first strand, said second strand, said third strand, said fourth strand, water, a buffer and at least one promoter; and

25 incubating said hybridization medium for an incubation time effective to hybridize said second strand to said fourth strand to provide said multiplex structure.

30 27. The method of claim 26, wherein said hybridization medium is buffered to a pH of about 5 to about 9.

28. The method of claim 26, wherein said at least one promoter is an intercalating agent.

29. The method of claim 28, wherein said at least one promoter is an intercalating fluorophore, and a fluorescent intensity of a test medium containing said multiplex structure is directly correlated with a binding affinity of said second strand for said fourth strand.

30. The method of claim 29, wherein said intercalating fluorophore is a member selected from the group consisting of YOYO-1, TOTO-1, ethidium bromide, ethidium homodimer-1, ethidium homodimer-2 and acridine.

31. The method of claim 26, wherein said at least one promoter is tethered to at least one of said first strand, said second strand, said third strand and said fourth strand.

32. The method of claim 26, wherein said at least one promoter is a monovalent cation.

33. The method of claim 26, wherein said at least one promoter is a cation having a valency greater than one.

34. The method of claim 33, wherein said cation is at least one member selected from the group consisting of alkali metal cations, alkaline earth metal cations, transition metal cations,  $\text{Co}(\text{NH}_3)_6^{+3}$ , trivalent spermidine and tetravalent spermine.

35. The method of claim 33, wherein said cation is  $\text{K}^+$  or  $\text{Na}^+$  provided at a concentration of 50mM to 125mM.

36. The method of claim 26, wherein said third strand and said fourth strand are provided in said hybridization medium before said first strand and said second strand, and wherein said first strand and said second strand are provided in dehydrated form prior to rehydration by contact with said hybridization medium.

37. The method of claim 26, wherein said incubation time is not more than about two hours.

38. The method of claim 26, wherein said incubating is conducted at room temperature.

39. The method of claim 26, wherein hybridization of said second strand to said fourth strand is detected as a change in a fluorescent, chemiluminescent, electrochemiluminescent or electrical signal.

40. The method of claim 39, wherein an intensity of said signal is correlated with a binding affinity between said second strand and said fourth strand.

41. The method of claim 40, wherein at least one of said first strand and said second strand is covalently labeled with a non-intercalating fluorophore and said intensity is inversely correlated with said binding affinity.

42. The method of claim 41, wherein said non-intercalating fluorophore is a member selected from the group consisting of biotin, rhodamine and fluorescein.

43. The method of claim 41, wherein said method is a homogeneous assay conducted without providing a signal quenching agent on said target sequence or on said probe.

44. The method of claim 26, wherein hybridization of said second strand to said fourth strand inactivates an activity associated with at least one of said third strand and said fourth strand.

45. The method of claim 26, wherein at least one of said first strand and said second strand further comprises a pharmaceutical agent, and wherein hybridization of said second strand to said fourth strand places said pharmaceutical agent an effective distance from a target on said third strand, said fourth strand or on another molecule associated with at least one of said third strand and said fourth strand.

46. The method of claim 45, wherein said pharmaceutical agent is a member selected from the group consisting of nucleic acids designed to bind promoter sequences of clinically relevant genes, nucleic acids designed to bind clinically relevant genes, or nucleic acids designed to bind origin of replication sites of pathogens.

47. The method of claim 26, wherein a ratio of said first strand and said second strand to said third strand and said fourth strand is about 10:1.

48. The method of claim 26, wherein concentrations of each of said first strand, said second strand, said third strand and said fourth strand are not more than  $5 \times 10^{-10}$  M.

49. The method of claim 26, wherein said at least one promoter is a minor groove nucleic acid binding molecule, which binds in a non-intercalating manner and binds with an association constant of at least  $10^3 \text{ M}^{-1}$ .

50. The multiplex structure of claim 1, wherein said first strand is associated with said third strand by Watson-Crick bonding.

51. An electrical circuit comprising the multiplex structure of claim 1.

52. A method for assaying binding, said method comprising:

providing a target nucleic acid or nucleic acid analogue having a target sequence, wherein said target sequence contains at least one purine base and at least one pyrimidine base;

providing a double-stranded probe comprising a nucleic acid sequence or a nucleic acid analog sequence; providing a hybridization promoter;

adding said probe, said target and said hybridization promoter to a medium to provide a test sample

containing a Watson-Crick triplex or quadruplex  
comprising said probe bound to said target  
sequence;

irradiating said test sample with exciting radiation  
to cause test sample to emit fluorescent  
radiation;

detecting an intensity of said fluorescent radiation,  
wherein said intensity is correlated with a  
binding affinity between said probe and said  
target sequence; and


determining from said intensity an extent of matching  
between said probe and said target sequence.

ABSTRACT OF THE DISCLOSURE


5 A multiplex structure, such as a nucleic acid  
quadruplex, includes: a first strand containing a first  
sequence of nucleobases; a second strand containing a  
second sequence of nucleobases, wherein the second strand  
is associated with the first strand by Watson-Crick  
bonding; a third strand containing a third sequence of  
nucleobases; and a fourth strand containing a fourth  
sequence of nucleobases, wherein the fourth strand is  
10 associated with the second strand and the third strand by  
Watson-Crick bonding. Formation of the multiplex structure  
is promoted by monovalent cations (e.g., sodium and  
potassium), divalent cations, multivalent cations,  
intercalating agents and/or molecules known to bind within  
15 the minor grooves of nucleic acids. The multiplex  
structure and the process of forming it have diagnostic,  
therapeutic, prophylactic and nanoengineering applications.




**FIG. 1. Mix of 15-mer dsDNA-F (4 pmole) (53% GC) and 50-mer dsDNA (0.4 pmole) in the presence of 100 mM KCl (after 1 hr)**




**FIG. 2. Mix of 15-mer dsDNA-F (4 pmole) (53% GC) and 50-mer dsDNA (0.4 pmole) in the presence of divalent cations (after 1 hr)**




**FIG. 3. Mix of 15-mer dsDNA (4 pmole) (53% GC) and 50-mer dsDNA (0.4 pmole) in the presence of 100 nM YOYO-1**



**FIG. 4. Mix of 15-mer dsDNA (4 pmole) (53% GC) and 50-mer dsDNA (0.4 pmole) in the presence of 100 nM YOYO-1**



**FIG. 5. Mix of 15-mer dsDNA (4 pmole) (53% GC) and 50-mer ssDNA (0.4 pmole) in the presence of 100 nM YOYO-1**



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

QUADRUPLEX DNA AND DUPLEX PROBE SYSTEMS

the specification of which is attached hereto unless the following box is checked:

Was filed on \_\_\_\_\_ as United States Application Number or PCT International Application

☐ Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35 U.S.C. §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed

Prior Foreign Application(s)

Priority Not Claimed

None			<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
_____	_____	_____	

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

None	
(Application Number)	(Filing Date)
_____	_____
(Application Number)	(Filing Date)
_____	_____

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

None		
(Application Number)	(Filing Date)	(Status-patented, pending, abandoned)
_____	_____	_____
(Application Number)	(Filing Date)	(Status-patented, pending, abandoned)
_____	_____	_____

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

Alan H. Bernstein (Registration No. 19,315), Stanley H. Cohen (Registration No. 20,235), Manny D. Pokotilow (Registration No. 22,492); Barry A. Stein (Registration No. 25,257); Martin L. Faigus (Registration No. 24,364); Eric S. Marzluf (Registration No. 27,454), Robert S. Silver (Registration No. 35,681); Scott M. Slomowitz (Registration No. 39,032); Michael J. Berkowitz (Registration No. 39,607), David M. Tener (Registration No. 37,054), James J. Kozuch (Registration No. 39,733), Frank M. Linguini (Registration No. 32,424), Gary A. Greene (Registration No. 38,897), Marilou E. Watson, (Registration No. 42,213), Michael J. Cornelison (Registration No. 40,395) and Christopher Marrone (Registration No. 45,101), care of Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., 12th Floor, Seven Penn Center, 1635 Market Street, Philadelphia, Pennsylvania 19103-2212, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name) Glen H. Erikson

Inventor's signature G. Erikson

Date 15 Sept 2000

Residence Providenciales, Turks and Caicos Islands, British West Indies

Citizenship Canada

Post Office Address The Sands, Providenciales, Turks and Caicos Islands, British West Indies

Full name of second joint inventor, if any (given name, family name) Jasmine I. Daksis

Second Inventor's signature Jasmine Daksis

Date 15 Sept 2000

Residence Richmond Hill, Ontario, Canada

Citizenship Canada

Post Office Address 36 Cartier Crescent, Richmond Hill, Ontario, Canada L4C 2N2

☐ Additional inventors are being named on separately numbered sheets attached hereto

E104720044-SeqListing.ST25  
SEQUENCE LISTING

<110> Erikson, Glen

<120> QUADRUPLEX DNA SYSTEM

<130> E1047/20044

<160> 15

<170> PatentIn version 3.0

<210> 1

<211> 50

<212> DNA

<213> synthetic construct

<400> 1

gagcaccatg acagacactg tcattctctgg tgtgtcctac gatgactctg

50

<210> 2

<211> 50

<212> DNA

<213> synthetic construct

<400> 2

cagagtcac gtaggacaca ccagagatga cagtgtctgt catggtgctc

50

<210> 3

<211> 50

<212> DNA

<213> synthetic construct

<400> 3

gagcaccatg acagacactg tcgtctctgg tgtgtcctac gatgactctg

50

<210> 4

<211> 50

<212> DNA

<213> synthetic construct

<400> 4

E104720044-SeqListing.ST25

cagagtcatc gtaggacaca ccagagacga cagtgtctgt catggtgctc  
50

<210> 5  
<211> 50  
<212> DNA  
<213> synthetic construct

<400> 5  
gagcaccatg acagacactg tcttctctgg tgtgtcctac gatgactctg  
50

<210> 6  
<211> 50  
<212> DNA  
<213> synthetic construct

<400> 6  
cagagtcatc gtaggacaca ccagagaaga cagtgtctgt catggtgctc  
50

<210> 7  
<211> 50  
<212> DNA  
<213> synthetic construct

<400> 7  
gagcaccatg acagacactg tcctctttgg tgtgtcctac gatgactctg  
50

<210> 8  
<211> 50  
<212> DNA  
<213> synthetic construct

<400> 8  
cagagtcatc gtaggacaca ccaaagatga cagtgtctgt catggtgctc  
50

<210> 9  
<211> 50  
<212> DNA  
<213> synthetic construct



<400> 9  
gagcaccatg acagacactg tcatccctgg tgtgtcctac gatgactctg  
50

<210> 10  
<211> 50  
<212> DNA  
<213> synthetic construct

<400> 10  
cagagtcatc gtaggacaca ccagggatga cagtgtctgt catggtgctc  
50

Seq  
#  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199

E104720044-SeqListing.ST25

<212> DNA

<213> synthetic construct

<400> 14

gtggtctcta ctgtc

15

<210> 15

<211> 50

<212> DNA

<213> synthetic construct

<400> 15

cagagtcacg gtaggacaca ccagcgatga cagtgtctgt catggtgctc

50